未登录

D

Dušan Ružić

University of Belgrade

H指数:13

被引数:499

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HDAC6 inhibition reverts docetaxel resistance in castration resistant prostate cancer

HDAC6抑制剂可逆转去势抵抗性前列腺癌中的多西他赛耐药性

Frontiers in Pharmacology

IF4.8

2026-11-110

OA

A computational framework for the design and development of ERK2 and multi-target ERK2/HDAC inhibitors

ERK2和多靶点ERK2/HDAC抑制剂的计算设计与发展框架

computational chemistry

IF3.1

2025-06-070

PRE

Pharmacological manipulation of liver fibrosis progression using novel HDAC6 inhibitors

使用新型HDAC6抑制剂进行肝纤维化进展的药理学调控

IF0

2025-03-140

OAAI

The histone deacetylase inhibitor Scriptaid targets G-quadruplexes

组蛋白去乙酰化酶抑制剂Scriptaid靶向G-四链体

IF3.6

2025-02-191

OA

Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents

FUTURE MEDICINAL CHEMISTRY

IF3.4

2025-01-300

PRE

Discovery and cellular delivery of BCL3 inhibitors for the potential treatment of advanced solid tumours with unmet medical need

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-010

PRE

Targeting noncoding RNAs to treat atherosclerosis

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2024-05-081

OAAI

Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer

靶向组蛋白去乙酰化酶6在肿瘤双靶点治疗中的应用

IF5.5

2023-11-0312

OAAI

Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma

PHARMACEUTICALS

IF4.8

2023-02-144

OAAI

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation

IF5.5

2022-11-2512

OAAI

Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions

JOURNAL OF MOLECULAR STRUCTURE

IF4.7

2022-06-0113

PRE

Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics

JOURNAL OF CHEMICAL INFORMATION AND MODELING

IF5.3

2022-04-259

OA

Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies

FUTURE MEDICINAL CHEMISTRY

IF3.4

2022-03-251

OA

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention

IF5.5

2022-01-1639

OAAI

Bistable Photoswitch Allows in Vivo Control of Hematopoiesis

ACS CENTRAL SCIENCE

IF10.4

2021-12-2215

OAAI

Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein

IF4.6

2021-08-319

OAAI

In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs

设计激酶抑制剂作为抗癌药物的计算机方法

FRONTIERS IN CHEMISTRY

IF4.2

2020-01-0882

OAAI

Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2019-05-096

OAAI

Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein column

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2016-08-0119

PREAI